118 related articles for article (PubMed ID: 15540780)
21. The effect of light fractionation with a 2-h dark interval on the efficacy of topical hexyl-aminolevulinate photodynamic therapy in normal mouse skin.
Middelburg TA; de Bruijn HS; van der Ploeg-van den Heuvel A; Neumann HA; Robinson DJ
Photodiagnosis Photodyn Ther; 2013 Dec; 10(4):703-9. PubMed ID: 24284130
[TBL] [Abstract][Full Text] [Related]
22. Hyperthermia enhances the antitumor effect of photodynamic therapy with ALA hexyl ester in a squamous cell carcinoma tumor model.
Yanase S; Nomura J; Matsumura Y; Kato H; Tagawa T
Photodiagnosis Photodyn Ther; 2012 Dec; 9(4):369-75. PubMed ID: 23200020
[TBL] [Abstract][Full Text] [Related]
23. Interstitial photodynamic therapy in subcutaneously implanted urologic tumors in rats after intravenous administration of 5-aminolevulinic acid.
Xiao Z; Tamimi Y; Brown K; Tulip J; Moore R
Urol Oncol; 2002; 7(3):125-32. PubMed ID: 12474546
[TBL] [Abstract][Full Text] [Related]
24. Biodistribution of hypericin in orthotopic transitional cell carcinoma bladder tumors: implication for whole bladder wall photodynamic therapy.
Kamuhabwa AA; Cosserat-Gerardin I; Didelon J; Notter D; Guillemin F; Roskams T; D'Hallewin MA; Baert L; de Witte PA
Int J Cancer; 2002 Jan; 97(2):253-60. PubMed ID: 11774272
[TBL] [Abstract][Full Text] [Related]
25. In vivo fluence rate and fractionation effects on tumor response and photobleaching: photodynamic therapy with two photosensitizers in an orthotopic rat tumor model.
Iinuma S; Schomacker KT; Wagnieres G; Rajadhyaksha M; Bamberg M; Momma T; Hasan T
Cancer Res; 1999 Dec; 59(24):6164-70. PubMed ID: 10626808
[TBL] [Abstract][Full Text] [Related]
26. Whole bladder photodynamic therapy for orthotopic superficial bladder cancer in rats: a study of intravenous and intravesical administration of photosensitizers.
Xiao Z; Brown K; Tulip J; Moore RB
J Urol; 2003 Jan; 169(1):352-6. PubMed ID: 12478188
[TBL] [Abstract][Full Text] [Related]
27. Biodistribution of protoporphyrin IX in rat urinary bladder after intravesical instillation of 5-aminolevulinic acid.
Chang SC; MacRobert AJ; Bown SG
J Urol; 1996 May; 155(5):1744-8. PubMed ID: 8627876
[TBL] [Abstract][Full Text] [Related]
28. Monitoring ALA-induced PpIX photodynamic therapy in the rat esophagus using fluorescence and reflectance spectroscopy.
Kruijt B; de Bruijn HS; van der Ploeg-van den Heuvel A; de Bruin RW; Sterenborg HJ; Amelink A; Robinson DJ
Photochem Photobiol; 2008; 84(6):1515-27. PubMed ID: 18557821
[TBL] [Abstract][Full Text] [Related]
29. Photodetection of early human bladder cancer based on the fluorescence of 5-aminolaevulinic acid hexylester-induced protoporphyrin IX: a pilot study.
Lange N; Jichlinski P; Zellweger M; Forrer M; Marti A; Guillou L; Kucera P; Wagnières G; van den Bergh H
Br J Cancer; 1999 Apr; 80(1-2):185-93. PubMed ID: 10389995
[TBL] [Abstract][Full Text] [Related]
30. Effect of photodynamic therapy on urinary bladder function: an experimental study with rats.
Grönlund-Pakkanen S; Pakkanen TM; Koski E; Talja M; Ala-Opas M; Alhava E
Urol Res; 2001 Jun; 29(3):205-9. PubMed ID: 11482448
[TBL] [Abstract][Full Text] [Related]
31. Monitoring the accumulation and dissipation of the photosensitizer protoporphyrin IX during standard dermatological methyl-aminolevulinate photodynamic therapy utilizing non-invasive fluorescence imaging and quantification.
Tyrrell J; Campbell SM; Curnow A
Photodiagnosis Photodyn Ther; 2011 Mar; 8(1):30-8. PubMed ID: 21333932
[TBL] [Abstract][Full Text] [Related]
32. The relationship between protoporphyrin IX photobleaching during real-time dermatological methyl-aminolevulinate photodynamic therapy (MAL-PDT) and subsequent clinical outcome.
Tyrrell JS; Campbell SM; Curnow A
Lasers Surg Med; 2010 Sep; 42(7):613-9. PubMed ID: 20806386
[TBL] [Abstract][Full Text] [Related]
33. Microscopic localisation of protoporphyrin IX in normal mouse skin after topical application of 5-aminolevulinic acid or methyl 5-aminolevulinate.
de Bruijn HS; Meijers C; van der Ploeg-van den Heuvel A; Sterenborg HJ; Robinson DJ
J Photochem Photobiol B; 2008 Aug; 92(2):91-7. PubMed ID: 18571933
[TBL] [Abstract][Full Text] [Related]
34. A comparative study of tissue distribution and photodynamic therapy selectivity of chlorin e6, Photofrin II and ALA-induced protoporphyrin IX in a colon carcinoma model.
Orenstein A; Kostenich G; Roitman L; Shechtman Y; Kopolovic Y; Ehrenberg B; Malik Z
Br J Cancer; 1996 Apr; 73(8):937-44. PubMed ID: 8611429
[TBL] [Abstract][Full Text] [Related]
35. Influence of light fluence rate on the effects of photodynamic therapy in an orthotopic rat glioma model.
Angell-Petersen E; Spetalen S; Madsen SJ; Sun CH; Peng Q; Carper SW; Sioud M; Hirschberg H
J Neurosurg; 2006 Jan; 104(1):109-17. PubMed ID: 16509154
[TBL] [Abstract][Full Text] [Related]
36. Protoporphyrin IX fluorescence photobleaching during ALA-mediated photodynamic therapy of UVB-induced tumors in hairless mouse skin.
Robinson DJ; de Bruijn HS; van der Veen N; Stringer MR; Brown SB; Star WM
Photochem Photobiol; 1999 Jan; 69(1):61-70. PubMed ID: 10063801
[TBL] [Abstract][Full Text] [Related]
37. Photodynamic therapy of bladder cancer - a phase I study using hexaminolevulinate (HAL).
Bader MJ; Stepp H; Beyer W; Pongratz T; Sroka R; Kriegmair M; Zaak D; Welschof M; Tilki D; Stief CG; Waidelich R
Urol Oncol; 2013 Oct; 31(7):1178-83. PubMed ID: 22440147
[TBL] [Abstract][Full Text] [Related]
38. Multispectral autofluorescence imaging for detection of cervical lesions: A preclinical study.
Bae SJ; Lee DS; Berezin V; Kang U; Lee KH
J Obstet Gynaecol Res; 2016 Dec; 42(12):1846-1853. PubMed ID: 27748558
[TBL] [Abstract][Full Text] [Related]
39. Protoporphyrin IX fluorescence photobleaching is a useful tool to predict the response of rat ovarian cancer following hexaminolevulinate photodynamic therapy.
Ascencio M; Collinet P; Farine MO; Mordon S
Lasers Surg Med; 2008 Jul; 40(5):332-41. PubMed ID: 18563777
[TBL] [Abstract][Full Text] [Related]
40. Photodynamic therapy for superficial bladder cancer under local anaesthetic.
Shackley DC; Briggs C; Gilhooley A; Whitehurst C; O'Flynn KJ; Betts CD; Moore JV; Clarke NW
BJU Int; 2002 May; 89(7):665-70. PubMed ID: 11966622
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
